VGO-Cs01p
/ Shanghai Vitalgen BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 15, 2025
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Initiation date: Feb 2025 ➔ Jul 2025
Trial initiation date • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD7
April 02, 2025
A single-arm, open label clinical study to evaluate the safety and efficacy of VGO-Cs01p in patients with CD7-positive relapsed/refractory acute T-lymphoblastic leukemia
(ChiCTR)
- P=N/A | N=9 | Not yet recruiting | Sponsor: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiao Tong Universit
New trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD7
February 27, 2025
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine
New P1 trial • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia
1 to 3
Of
3
Go to page
1